BCM
GALT icon

Brookstone Capital Management’s Galectin Therapeutics GALT Stock Holding History

Brookstone Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,560
Closed -$27K – 724
2021
Q1 		$27K Sell
12,560
-150
-1% -$336 ﹤0.01% 501
2020
Q4 		$28K Hold
12,710
– – ﹤0.01% 466
2020
Q3 		$34K Buy
+12,710
New +$35.6K ﹤0.01% 438
2020
Q2 		– Sell
-10,150
Closed -$20K – 376
2020
Q1 		$20K Buy
+10,150
New +$24.7K ﹤0.01% 329

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brookstone Capital Management's GALT Position: Q2 2021 in Review

Brookstone Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 12,560 shares — an estimated $27K sold.

Brookstone Capital Management first reported a position in GALT in Q1 2020 and held it in 4 quarters. The position peaked at $34K in Q3 2020. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

  • Brookstone Capital Management reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brookstone Capital Management sold 12,560 Galectin Therapeutics shares in Q2 2021, an estimated $27K.
  • Brookstone Capital Management first reported a position in Galectin Therapeutics in Q1 2020 and held it in 4 quarters.
  • Brookstone Capital Management's Galectin Therapeutics position peaked at $34K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on Brookstone Capital Management's 13F filing for Q2 2021, filed 14 Jul 2021.